• Chosa Oncology posted a loss after financial items of SEK 1.87 million for Q1 2026, widening from SEK 1.81 million a year earlier.
• Diluted loss per share narrowed to SEK 0.021 from SEK 0.025.
• Other operating income was no revenue versus SEK 2,000 a year earlier, while equity ratio rose 1 percentage point to 91%.
• CEO Peter Buhl Jensen said Q2 brought progress toward broader clinical use and commercialization of Platin-DRP, including new international lung-cancer collaborations.
• Post-period, Chosa set a TO2 warrant exercise price of SEK 0.78, appointed Bill Cronin to lead US commercialization, and reported TO2 exercise results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chosa Oncology AB published the original content used to generate this news brief via Cision (Ref. ID: 202608270230BITN____UKPR__SV_20260826-BIT-2596-0) on August 27, 2026, and is solely responsible for the information contained therein.